SOPHiA Genetics, Hitachi collaborate on data-driven precision medicine

SOPHiA Genetics and Hitachi announced Thursday that they entered into a long-term partnership that seeks to "unlock the potential of multimodal health data" to advance data-driven precision medicine. The collaboration will focus on global commercial expansion, plus on developing Hitachi's digital healthcare solutions as well as the former's cloud-based SOPHiA DDM analytics platform for clinical genomics.

The companies said they have identified "multiple" potential areas to collaborate on, including secure personal genomics data management, deploying data and insights to make better healthcare decisions, and speeding up drug development for oncology and other diseases.

The partnership will initially focus on leveraging the companies' expertise in genomics, clinical data analytics and artificial intelligence to expand the commercialisation of the SOPHiA DDM platform and Hitachi's digital healthcare solutions, such as its molecular tumour board support service, in key geographies. Over the long term, the two will also work together on R&D-related new product development that they say could lead to new joint offerings.

Last October, SOPHiA Genetics said it raised $110 million in an oversubscribed Series F funding round co-led by Hitachi Ventures and aMoon. At the time, SOPHiA Genetics indicated that the funds would be used to enter into the next stage of its global expansion, focusing on the "growing clinical and biopharma demand" for data-driven medicine.

To ensure you don't miss news stories and features like these, sign up for our free daily e-newsletter here.

Did you like this article?